Results 91 to 100 of about 315,915 (340)
Activation of the alternative complement pathway by Sporothrix schenckii [PDF]
We studied the activation of complement by Sporothrix schenckii yeast cells. Total complement activity, and the effect of various activators on this activity, were assayed on aliquots of fresh nonimmune human serum with and without prior treatment with chelators.
H G Muchmore, E N Scott, D P Fine
openaire +3 more sources
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci+6 more
wiley +1 more source
Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren+16 more
wiley +1 more source
Urine Complement Proteins and the Risk of Kidney Disease Progression and Mortality in Type 2 Diabetes. [PDF]
ObjectiveWe examined the association of urine complement proteins with progression to end-stage renal disease (ESRD) or death in people with type 2 diabetes and proteinuric diabetic kidney disease (DKD).Research design and methodsUsing targeted mass ...
Afkarian, Maryam+6 more
core +1 more source
Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. [PDF]
The alternative pathway of complement is implicated in the pathogenesis of several renal diseases, such as atypical hemolytic uremic syndrome, dense deposit disease and other forms of C3 glomerulopathy.
Józsi, Mihály+6 more
core +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop+10 more
wiley +1 more source
Kidney Diseases Caused by Complement Dysregulation: Acquired, Inherited, and Still More to Come
Inherited and acquired dysregulation of the complement alternative pathway plays an important role in multiple renal diseases. In recent years, the identification of disease-causing mutations and genetic variants in complement regulatory proteins has ...
Saskia F. Heeringa, Clemens D. Cohen
doaj +1 more source
Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury
Background: Hypoxic-ischemic (HI) encephalopathy is a major cause of neonatal mortality and morbidity, with a global incidence of 3 per 1,000 live births.
Claudia Sisa+5 more
doaj +1 more source
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski+19 more
wiley +1 more source
Complement depletion during haemofiltration with polyacrilonitrile membranes [PDF]
Background Polyacrylonitrile (PAN, AN69®) dialysis membranes have been shown to improve the outcome of critically ill patients. Factor D is an essential enzyme of the alternative pathway of complement and is increased during renal failure.
Chevrolet, Jean-Claude+5 more
core